Cytek Biosciences, Inc. CTKB
We take great care to ensure that the data presented and summarized in this overview for Cytek Biosciences, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CTKB
View all-
Black Rock Inc. New York, NY17.4MShares$95 Million0.0% of portfolio
-
Brown Capital Management LLC Baltimore, MD12MShares$65.5 Million1.45% of portfolio
-
Vanguard Group Inc Valley Forge, PA12MShares$65.5 Million0.0% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E96.66MShares$36.3 Million0.99% of portfolio
-
State Street Corp Boston, MA4.12MShares$22.4 Million0.0% of portfolio
-
New York State Common Retirement Fund2.95MShares$16.1 Million0.03% of portfolio
-
Geode Capital Management, LLC Boston, MA2.51MShares$13.7 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX1.38MShares$7.5 Million0.0% of portfolio
-
Wellington Management Group LLP Boston, MA1.35MShares$7.38 Million0.0% of portfolio
-
Northern Trust Corp Chicago, IL1.13MShares$6.16 Million0.0% of portfolio
Latest Institutional Activity in CTKB
Top Purchases
Top Sells
About CTKB
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system, which leverages full spectrum profiling technology to further broaden potential applications across cell analysis. The company also provides reagents and kits, including cFluor reagents, which are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, which are automated plate loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific region; and through distributors or sales agents in European, Latin American, the Middle Eastern, and the Asia-Pacific countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
Insider Transactions at CTKB
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
May 20
2024
|
Allen Poirson SVP BUS. AND CORP. DEV. |
SELL
Payment of exercise price or tax liability
|
Direct |
1,447
-0.9%
|
$7,235
$5.96 P/Share
|
May 20
2024
|
Allen Poirson SVP BUS. AND CORP. DEV. |
BUY
Exercise of conversion of derivative security
|
Direct |
3,711
+2.26%
|
-
|
May 20
2024
|
Paul Christopher Williams CHIEF OPERATING OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
2,927
-9.56%
|
$14,635
$5.96 P/Share
|
May 20
2024
|
Paul Christopher Williams CHIEF OPERATING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
7,512
+18.29%
|
-
|
May 20
2024
|
Ming Yan CHIEF TECHNOLOGY OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
3,137
-0.02%
|
$15,685
$5.96 P/Share
|
May 20
2024
|
Ming Yan CHIEF TECHNOLOGY OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
10,572
+0.06%
|
-
|
May 20
2024
|
Valerie Barnett CHIEF LEGAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
3,751
-3.01%
|
$18,755
$5.96 P/Share
|
May 20
2024
|
Valerie Barnett CHIEF LEGAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
9,626
+7.1%
|
-
|
May 20
2024
|
Wenbin Jiang PRESIDENT AND CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
7,102
-0.04%
|
$35,510
$5.96 P/Share
|
May 20
2024
|
Wenbin Jiang PRESIDENT AND CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
29,345
+0.18%
|
-
|
May 20
2024
|
Philippe Busque SVP, GLOBAL SALES AND SERVICES |
SELL
Payment of exercise price or tax liability
|
Direct |
3,168
-16.21%
|
$15,840
$5.96 P/Share
|
May 20
2024
|
Philippe Busque SVP, GLOBAL SALES AND SERVICES |
BUY
Exercise of conversion of derivative security
|
Direct |
8,132
+27.11%
|
-
|
Apr 19
2024
|
Ming Yan CHIEF TECHNOLOGY OFFICER |
SELL
Open market or private sale
|
Direct |
20,000
-0.33%
|
$100,000
$5.87 P/Share
|
Apr 09
2024
|
Ming Yan CHIEF TECHNOLOGY OFFICER |
SELL
Open market or private sale
|
Direct |
1,900
-0.02%
|
$13,300
$7.01 P/Share
|
Mar 20
2024
|
Philippe Busque SVP, GLOBAL SALES AND SERVICES |
SELL
Payment of exercise price or tax liability
|
Direct |
2,129
-38.96%
|
$12,774
$6.7 P/Share
|
Mar 20
2024
|
Philippe Busque SVP, GLOBAL SALES AND SERVICES |
BUY
Exercise of conversion of derivative security
|
Direct |
5,464
+50.0%
|
-
|
Mar 19
2024
|
Ming Yan CHIEF TECHNOLOGY OFFICER |
SELL
Open market or private sale
|
Direct |
20,000
-0.33%
|
$120,000
$6.71 P/Share
|
Mar 18
2024
|
Ming Yan CHIEF TECHNOLOGY OFFICER |
SELL
Open market or private sale
|
Direct |
20,000
-0.33%
|
$120,000
$6.77 P/Share
|
Mar 11
2024
|
Ming Yan CHIEF TECHNOLOGY OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
2,911
-0.05%
|
$20,377
$7.22 P/Share
|
Mar 11
2024
|
Ming Yan CHIEF TECHNOLOGY OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
9,817
+0.16%
|
-
|
Last 12 Months Summary
Exercise of conversion of derivative security | 224K shares |
---|---|
Open market or private sale | 3K shares |
Payment of exercise price or tax liability | 76.2K shares |
---|---|
Bona fide gift | 3.99M shares |
Open market or private sale | 320K shares |